A Phase 3 interventional study of Arsenic trioxide and Low-dose cytarabine alone in Acute Myeloid Leukemia, sponsored by Cephalon. Terminated at 12 sites in 2 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2012-08-01.
Sponsored by Cephalon (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing Arsenic Trioxide in Leukemia, Myeloid, Acute — 2 open to participants now, 2 under way, none of them phase 3. Arsenic Trioxide · Leukemia, Myeloid, Acute.
Among the 14 studies testing Arsenic Trioxide in Leukemia, Myeloid, Acute, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2007, is the only one in phase 3, and was the 8th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →2 of the 14 studies testing Arsenic Trioxide in Leukemia, Myeloid, Acute are open now, in 2 countries. Recruiting first, the newest first:
University of Michigan Rogel Cancer Center · Sites in United States
Ages 21+
The University of Hong Kong · Sites in Hong Kong
Ages 18+
By country, each count listing its studies:
Arsenic Trioxide: first FDA approval 2000 (TRISENOX), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 1
First in 1997; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is above the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 13 across the 13 interventional studies. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 14 have an industry lead sponsor. The 10 most frequent:
This study is registered under Cephalon, one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Cephalon is the lead sponsor of 75 studies on the registry; none are open to participants now.
Teva Pharmaceutical Industries, Ltd. has 2 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
1 of the studies testing Arsenic Trioxide in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06778187The University of Hong KongOral-ATO for TP53-mutated Myeloid Malignancies | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing Arsenic Trioxide in Leukemia, Myeloid, Acute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine whether low-dose cytarabine in combination with arsenic trioxide is more effective than low-dose cytarabine alone in achieving complete remission in elderly patients (≥60 years of age) with acute myeloid leukemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Previous treatment with low-dose cytarabine is not permitted.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cycle 1 cytarabine 10 mg/m\^2 was administered subcutaneously (sc) twice daily (bid) on days 1-14. 0.25 mg/kg arsenic trioxide was administered intravenously (iv) on days 1-5 and days 8-12. Cycle 2 A second identical cycle of cytarabine and arsenic trioxide was given to patients with persistent disease. Patients who achieved complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine and arsenic trioxide with the doses and schedule identical to the initial cycle. A recovery period of up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of arsenic trioxide 0.25 mg/kg iv on days 1 and 4 and cytarabine 10 mg/m\^2 sc bid on days 1 through 7 of a 28-day cycle.
Drug: Arsenic trioxide · Drug: Low-dose cytarabine alone
Cytarabine was administered at a dose of 10 mg/m\^2 sc bid from days 1-14 of cycle 1. A second identical cycle of cytarabine was given to patients with persistent disease. Patients who achieved a complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine with the doses and schedule identical to the initial treatment cycle. Recovery period up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of cytarabine at 10 mg/m\^2 sc bid on days 1-7 of a 28-day cycle. Patients started maintenance treatment within 42 days after platelet count recovery. Maintenance treatment continued for 2 years or until unacceptable toxicity or disease progression.
Drug: Low-dose cytarabine alone
Arsenic trioxide will be administered intravenously (iv) at a dose of 0.25 mg/kg.
Cytarabine will be administered at a dose of 10 mg/m\^2 subcutaneously (sc) twice a day (bid).
Percentage of Participants in Complete Remission (CR)
The primary efficacy variable was the percentage of subjects in each treatment group who achieved complete remission after treatment with study drug. Complete remission was defined as: 1) Less than 5% blasts in normocellular bone marrow sample. 2) No blasts in bone marrow sample containing Auer rods. 3)Clearance of previous extramedullary disease. 4)Normal values for absolute neutrophil count (at least 1000/microliter), platelet count (at least 100,000/microliter), without platelet transfusions, and in absence of peripheral myeloblasts.
Time frame: From baseline through Day 70. Assessments were performed on Day 21 in cycle 1, no later than Day 56 of cycle 1 or 2 (if applicable), and no later than Day 70 of cycle 1 or 2 (if applicable) or at any other time at the discretion of the investigator
Number of Participants Who Died or Were Censored by 24 Months
This measure (time to death or censor) was defined for all enrolled subjects from the date of randomization until death from any cause. If a subject was not known to have died by the end of the followup period, observation of overall survival was censored on the date the patient was last known to be alive. The number of participants who died or were censored is presented here. (Note: all subjects participating in this study had either died or were censored by 24 months.)
Time frame: From Baseline through 24 months following Baseline
Proportion of Participants With Relapse-Free Survival (RFS)Using the Kaplan-Meier Estimate
RFS is defined for patients who achieved a complete remission (CR), complete remission with incomplete platelet recovery (CRp), or partial remission(PR), and was measured from the date of attaining CR, CRp, or PR until the date of AML relapse or death from any cause, whichever occurred first. For a patient not known to have relapsed or died by the end of the study followup, observation of relapse free survival was censored on the date of the last followup examination. The Kaplan Meier Estimate of relapse-free survival at Month 3 and Month 6 is presented here.
Time frame: From Baseline (randomization) through 24 months following Baseline
Number of Participants Who Experienced Early Death
Early death is defined as death from any cause within the first 14 days after start of study drug treatment. The number of patients in each study group who experienced early death is presented here.
Time frame: 14 days from start of study drug treatment
Number of Participants Who Experienced Induction (Thirty-Day) Mortality
The number of subjects who died from any cause within the first 30 days after the start of study drug treatment is presented here.
Time frame: Up to 30 days following start of study drug treatment
Proportion of Participants Surviving at 6 Months and 12 Months Using the Kaplan Meier Estimate
The duration of overall survival was defined for all patients and was measured from the date of randomization until death from any cause. For a patient who was not known to have died by the end of the follow-up period, observation of overall survival was censored on the date the patient was last known to be alive. The estimate of likelihood of survival at 6 and 12 months after Baseline using the Kaplan Meier Estimate is presented here.
Time frame: Baseline through 12 months
Seven centers in the United States and one center in Canada. First patient enrolled 12 October 2007; last patient completed protocol-specified treatment 5 July 2009; last patient completed survival follow-up contact 16 December 2009.
| Milestone | Low-dose Cytarabine Plus Arsenic Trioxide | Low-dose Cytarabine Alone |
|---|---|---|
| Started | 33 | 34 |
| Completed | 5 | 7 |
| Not completed | 28 | 27 |
| Withdrew: Adverse event | 6 | 2 |
| Withdrew: Death (through consolidation treatment) | 2 | 2 |
| Withdrew: Lack of efficacy | 8 | 13 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Disease progression | 8 | 5 |
| Withdrew: Eligible for stem cell transplant | 1 | 0 |
| Withdrew: Hematologic counts did not recover | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Persistent hypocellularity | 0 | 1 |
| Withdrew: Sponsor decision | 0 | 2 |
The primary efficacy variable was the percentage of subjects in each treatment group who achieved complete remission after treatment with study drug. Complete remission was defined as: 1) Less than 5% blasts in normocellular bone marrow sample. 2) No blasts in bone marrow sample containing Auer rods. 3)Clearance of previous extramedullary disease. 4)Normal values for absolute neutrophil count (at least 1000/microliter), platelet count (at least 100,000/microliter), without platelet transfusions, and in absence of peripheral myeloblasts.
| Percentage of participants in CR | Low-dose Cytarabine Plus Arsenic Trioxide | Low-dose Cytarabine Alone |
|---|---|---|
| Percentage of Participants in Complete Remission (CR) | 15.2 (0.051 to 0.319) | 8.8 (0.019 to 0.0237) |
This measure (time to death or censor) was defined for all enrolled subjects from the date of randomization until death from any cause. If a subject was not known to have died by the end of the followup period, observation of overall survival was censored on the date the patient was last known to be alive. The number of participants who died or were censored is presented here. (Note: all subjects participating in this study had either died or were censored by 24 months.)
| Participants | Low-dose Cytarabine Plus Arsenic Trioxide | Low-dose Cytarabine Alone |
|---|---|---|
| Number of Participants Who Died or Were Censored by 24 Months | 33 | 34 |
RFS is defined for patients who achieved a complete remission (CR), complete remission with incomplete platelet recovery (CRp), or partial remission(PR), and was measured from the date of attaining CR, CRp, or PR until the date of AML relapse or death from any cause, whichever occurred first. For a patient not known to have relapsed or died by the end of the study followup, observation of relapse free survival was censored on the date of the last followup examination. The Kaplan Meier Estimate of relapse-free survival at Month 3 and Month 6 is presented here.
| Proportion of participants | Low-dose Cytarabine Plus Arsenic Trioxide | Low-dose Cytarabine Alone |
|---|---|---|
| Month 3 (95% Confidence Interval) | 0.818 (0.447 to 0.951) | 0.800 (0.204 to 0.969) |
| Month 6 (95% Confidence Interval) | 0.818 (0.447 to 0.951) | 0.800 (0.204 to 0.969) |
Early death is defined as death from any cause within the first 14 days after start of study drug treatment. The number of patients in each study group who experienced early death is presented here.
| Participants | Low-dose Cytarabine Plus Arsenic Trioxide | Low-dose Cytarabine Alone |
|---|---|---|
| Number of Participants Who Experienced Early Death | 0 | 2 |
The number of subjects who died from any cause within the first 30 days after the start of study drug treatment is presented here.
| Participants | Low-dose Cytarabine Plus Arsenic Trioxide | Low-dose Cytarabine Alone |
|---|---|---|
| Number of Participants Who Experienced Induction (Thirty-Day) Mortality | 3 | 2 |
The duration of overall survival was defined for all patients and was measured from the date of randomization until death from any cause. For a patient who was not known to have died by the end of the follow-up period, observation of overall survival was censored on the date the patient was last known to be alive. The estimate of likelihood of survival at 6 and 12 months after Baseline using the Kaplan Meier Estimate is presented here.
| Proportion of Participants | Low-dose Cytarabine Plus Arsenic Trioxide | Low-dose Cytarabine Alone |
|---|---|---|
| Month 6 (95% Confidence Interval) | 0.626 (0.435 to 0.768) | 0.649 (0.454 to 0.789) |
| Month 12 (95% Confidence Interval) | 12.22 (4.37 to 16.76) | 8.51 (5.72 to 19.65) |
Collected over approximately 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low-dose Cytarabine Plus Arsenic Trioxide | — | 19/33 (57.6%) | 33/33 (100%) |
| Low-dose Cytarabine Alone | — | 21/33 (63.6%) | 33/33 (100%) |
| Event | Low-dose Cytarabine Plus Arsenic Trioxide | Low-dose Cytarabine Alone |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 7/33 | 9/33 |
| PneumoniaInfections and infestations | 3/33 | 3/33 |
| DehydrationMetabolism and nutrition disorders | 1/33 | 2/33 |
| Lung infiltrationRespiratory, thoracic and mediastinal disorders | 0/33 | 2/33 |
| Neutropenic sepsisInfections and infestations | 2/33 | 1/33 |
| Pneumonia fungalInfections and infestations | 2/33 | 0/33 |
| Renal failureRenal and urinary disorders | 2/33 | 0/33 |
| Renal failure acuteRenal and urinary disorders | 1/33 | 2/33 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 2/33 | 1/33 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/33 | 0/33 |
| Event | Low-dose Cytarabine Plus Arsenic Trioxide | Low-dose Cytarabine Alone |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 21/33 | 14/33 |
| Febrile neutropeniaBlood and lymphatic system disorders | 9/33 | 16/33 |
| Oedema peripheralGeneral disorders | 16/33 | 14/33 |
| NauseaGastrointestinal disorders | 15/33 | 9/33 |
| ConstipationGastrointestinal disorders | 14/33 | 11/33 |
| HypotensionVascular disorders | 13/33 | 9/33 |
| PyrexiaGeneral disorders | 9/33 | 12/33 |
| FatigueGeneral disorders | 10/33 | 9/33 |
| HeadacheNervous system disorders | 10/33 | 4/33 |
| TachycardiaCardiac disorders | 6/33 | 10/33 |
| Age, Categorical(Participants) | Low-dose Cytarabine Plus Arsenic Trioxide | Low-dose Cytarabine Alone | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 7 | 16 |
| >=65 years | 24 | 27 | 51 |
| Age Continuous(years) | Low-dose Cytarabine Plus Arsenic Trioxide | Low-dose Cytarabine Alone | Total |
|---|---|---|---|
| Mean | 70.9 ± 7.1 | 71.5 ± 6.8 | 71.2 ± 6.9 |
| Sex: Female, Male(Participants) | Low-dose Cytarabine Plus Arsenic Trioxide | Low-dose Cytarabine Alone | Total |
|---|---|---|---|
| Female | 16 | 17 | 33 |
| Male | 17 | 17 | 34 |
| Region of Enrollment(participants) | Low-dose Cytarabine Plus Arsenic Trioxide | Low-dose Cytarabine Alone | Total |
|---|---|---|---|
| United States | 32 | 32 | 64 |
| Canada | 1 | 2 | 3 |
The record gives a start of Oct 2007, a primary completion of Jul 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arsenic Trioxide